Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial

Arndtz, Katherine; Chen, Yung-Yi; Rowe, Anna; Homer, Victoria; Kirkham, Amanda; Douglas-Pugh, Jessica; Slade, Daniel; Thorburn, Douglas; Barnes, Eleanor; Aithal, Guruprasad; Newsome, Philip; Smith, David; Adams, David; Weston, Christopher; Hirschfield, Gideon

doi:10.3310/ZPNF4670

Graphic version of this page | Change how these pages look

Journals Library

NHS NIHR - National Institute for Health and Care Research

Journals

Twitter
Facebook
LinkedIn
Email

An error occurred retrieving content to display, please try again.

Home >> Journals >> Efficacy and Mechanism Evaluation >> Page Not Found

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Home >> Journals >> Efficacy and Mechanism Evaluation >> Volume {{metadata.Volume}} >> Issue {{metadata .Issue }}
Extended Research Article
i

Toolkit

View Award

This trial did not show any evidence of efficacy of BTT1023 and as per the protocol and the design of the trial it was discontinued.

Detailed Author information
Detailed Author information

Katherine Arndtz ¹, Yung-Yi Chen ¹, Anna Rowe ², Victoria Homer ², Amanda Kirkham ², Jessica Douglas-Pugh ², Daniel Slade ², Douglas Thorburn ³, Eleanor Barnes ⁴, Guruprasad Aithal ⁵, Philip Newsome ¹, David Smith ⁶, David Adams ¹, Christopher Weston ¹, Gideon Hirschfield ^1,^*

¹ Institute of Biomedical Research, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK
² Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
³ Liver Services, Royal Free London NHS Foundation Trust, London, UK
⁴ Nuffield Department of Medicine, University of Oxford, Oxford, UK
⁵ Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, UK
⁶ Acorda Therapeutics, Inc., Ardsley, NY, USA
^* Corresponding author Email: gideonhirschfield@gmail.com

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

[Image - Crossmark status check]

Report Content

Full Report
Abstract
Plain English Summary
Plain Language Summary
Scientific Summary

The full text of this issue is available as a PDF document from the Toolkit section on this page.

Responses to this report

No responses have been published.

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors. Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

Enter response message*
Name (title, first name, last name)*
Occupation / Job title*
Affiliation / Employer*
Email*
Other authors
For example, if you are responding as a team or group. Please ensure you include full names and separate these using commas
Statement of competing interestsWe believe that readers should be aware of any competing interests (conflicts of interest).The International Committee of Medical Journal Editors (ICMJE) define competing interests as including: financial relationships with industry (for example through employment, consultancies, stock, ownership, honoraria, and expert testimony), either directly or through immediate family; personal relationships; academic competition; and intellectual passion.
If yes, please provide details below
Enter response title*
Enter CAPTCHA What is eight multiplied by four?*

By submitting your response, you are stating that you agree to the terms & conditions